SIS3

SIS3

Catalog Number:
L002371427APE
Mfr. No.:
APE-B6096
Price:
$209
  • Size:
    Quantity:
    Add to Cart:
      • Overview
        • Please contact us at for specific academic pricing.

          Background

          IC50: 3 μM
          SIS3 is an inhibitor of Smad3.
          The receptor-associated Smads, such as Smad2 and Smad3, directly interact with activated TGF-receptor type I. Smads form heteromeric complexes with Smad4, which is a common mediator for all Smad pathways.
          In vitro: In the reporter assay, it was found that the increased luciferase activity of p3TP-lux could be abrogated by the SIS3 treatment in a dosedependent manner. Immunoprecipitation revealed SIS3 attenuated the TGF-1-induced phosphorylation of Smad3 and interaction of Smad3 with Smad4. Whereas, SIS3 did not affect the phosphorylation of Smad2. In addition, it was found that SIS3 attenuated the effects of TGF-1 by reducing the transcriptional activity. SIS3 could also inhibit the myofibroblast differentiation of fibroblasts by TGF-1. Moreover, SIS3 diminished the constitutive phosphorylation of Smad3 completely [1].
          In vivo: Animal study showed that, in Tie2-Cre;Loxp-EGFP mice, AGEs could induce EndoMT. Immunoprecipitation and Western blotting showed that Smad3 could be activated by AGEs but was inhibited by SIS3 in both MMECs and in STZ-induced diabetic nephropathy. Furthermore, confocal microscopy and real-time PCR showed that SIS3 could abrogate EndoMT, reduce renal fibrosis, as well as retard nephropathy progression [2].
          Clinical trial: Up to now, SIS3 is still in the preclinical development stage.

          [1] Jinnin M et al. Characterization of SIS3, a novel specific inhibitor of Smad3, and its effect on transforming growth factor-beta1-induced extracellular matrix expression. Mol Pharmacol. 2006 Feb;69(2):597-607.
          [2] Li J et al. Blockade of endothelial-mesenchymal transition by a Smad3 inhibitor delays the early development of streptozotocin-induced diabetic nephropathy. Diabetes.2010 Oct;59(10):2612-24.

      • Properties
        • Alternative Name
          (E)-1-(6,7-dimethoxy-3,4-dihydroisoquinolin-2(1H)-yl)-3-(1-methyl-2-phenyl-1H-pyrrolo[2,3-b]pyridin-3-yl)prop-2-en-1-one hydrochloride
          CAS Number
          521984-48-5
          Molecular Formula
          C28H28ClN3O3
          Molecular Weight
          489.99
          Appearance
          A solid
          Purity
          98.00%
          Solubility
          ≥49 mg/mL in DMSO; insoluble in H2O; ≥11 mg/mL in EtOH with gentle warming and ultrasonic
          Storage
          Store at -20°C

          * For Research Use Only

      • Reference
        • 1. Dong Zeng, Zheng Xiao, et al. "Norcantharidin protects against renal interstitial fibrosis by suppressing TWEAK-mediated Smad3 phosphorylation." Life Sci. 2020 Nov 1;260:118488. PMID:32979359
          2. Yegodayev KM, Novoplansky O, et al. "TGF-Beta-Activated Cancer-Associated Fibroblasts Limit Cetuximab Efficacy in Preclinical Models of Head and Neck Cancer." Cancers (Basel). 2020;12(2):E339. PMID:32028632
          3. Liu W, Zhang D, et al. "TGF-β1 facilitates cell-cell communication in osteocytes via connexin43- and pannexin1-dependent gap junctions." Cell Death Discov. 2019 Oct 25;5:141. PMID:31666990

    We Also Recommend

    SU5614

    $220

    Note: If you don't receive our verification email, do the following:

    Copyright © Amerigo Scientific. All rights reserved.